ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline has teamed up with Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, to discover and develop microRNA-targeted drugs. Regulus will develop microRNA antagonists against four targets related to inflammatory disease through clinical proof of concept; GSK will then have the option to license those drugs for further development. GSK will pay Regulus $20 million up front plus up to $144.5 million in milestones for each target developed in the deal. MicroRNAs are small single-stranded RNAs that regulate the expression of many human genes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter